Home › Lung Cancer › NCT01580982
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
RecruitingObservational study
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies 2. Aged 18 years or older 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis. 4. Patients must have the ability to understand and willingness to sign an informed consent document. Exclusion Criteria: \-
About the study
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.
Sponsor: University of Colorado, Denver · Participants: 500 · Started: Jan 23, 2012
Contact the study team
- Brandi Kubala · Phone: 303-724-1657
Official record on ClinicalTrials.gov — NCT01580982
Locations in the U.S.
| Colorado | University of Colorado Cancer Center, Aurora |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.